Endo International Plc (ENDP)

7.93
NASDAQ
Prev Close 9.31
Day Low/High 7.78 / 9.14
52 Wk Low/High 2.08 / 10.89
Exchange NASDAQ
Shares Outstanding 230.29B
Market Cap 2.14B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Endo International Shares Climb on Earnings Beat

Endo International Shares Climb on Earnings Beat

Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.

Trending Tickers: NCLH, RCL, ENDP, DISH

Trending Tickers: NCLH, RCL, ENDP, DISH

Norwegian Cruise Line was pulling down industry-peer Royal Caribbean Tuesday on lowered guidance.

Endo International Jumps on Patent Approval, Still Has Work to Do

ENDP shares surge on rare good news but asset sales may still be necessary.

Trending Tickers: UAL, MNK, ENDP, BWA

Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.

Endo Could Be the Next Activist Target in Generics

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Teva Should Break Out of Droopy Drug Pack

Teva Should Break Out of Droopy Drug Pack

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer: Allergan CEO Brent Saunders Is Doing a Great Job

Jim Cramer thinks Allergan CEO Brent Saunders has put together a world class company.

Endo downgraded at RBC

Endo International Plunges After Hours as Guidance Slashed

The specialty pharmaceutical company gave investors a lot of news to digest -- and they fled.

Endo's Asset Sale May Signal Litigation Trouble; Shares Trail S&P 500

Endo's Asset Sale May Signal Litigation Trouble; Shares Trail S&P 500

the Sale of ASTORA Women's Health could bode well for the speciality pharma, as legal woes persist.

2 Great Biopharma Plays for a Shaky Market

2 Great Biopharma Plays for a Shaky Market

Mylan and Endo International look like bargains at current prices.

4 Great Stock-ing Stuffers for 2016

4 Great Stock-ing Stuffers for 2016

These biotech/pharma picks could give you a very happy new year.

BioDelivery Is About to Start Delivering

BioDelivery Is About to Start Delivering

The company cleared an important hurdle last month.

Endo downgraded at Morgan Stanley

Endo upgraded at RBC

Apple Drives Markets on Icahn Boost; Altera Sparks Chipmaker Rally

Apple Drives Markets on Icahn Boost; Altera Sparks Chipmaker Rally

Altera (ALTR) was the best performer on the S&P 500 Monday following reports the company has reopened negotiations with Intel (INTC).

Deluge of Deals Isn't About to Dry Up

Acquisitions cut into overabundance of companies.

Endo Buys Par Pharmaceutical; Intel, Altera Relaunch Deal Talks

Endo Buys Par Pharmaceutical; Intel, Altera Relaunch Deal Talks

Endo Pharmaceutical (ENDP) shares were on the move after the company agreed to buy privately-held Par Pharmaceutical Holdings for just over $8 billion in cash and stock.

Bear Chart of the Day: ENDP

Bear Chart of the Day: ENDP

Endo Pharmaceuticals could offer a short-term play.

Cramer: How Passive Is the S&P? (Part 2)

Cramer: How Passive Is the S&P? (Part 2)

Take a look at some more of its recent moves.

2 Solid Trees to Withstand This Storm

2 Solid Trees to Withstand This Storm

It's wise to stick with strength right now.

Merger Mania Benefits Mylan

Merger Mania Benefits Mylan

Whether it's acquiring or the acquired, Mylan is building shareholder value.

Endo upgraded at Morgan Stanley

Will Valeant Overdose on Acquisitions?

Will Valeant Overdose on Acquisitions?

This rollup name is on the stock-market equivalent of steroids.

Endo Health downgraded at Cantor

5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Avon Gets Dinged, Endo's Irish Eyes, Piper Pipes Down, Bye-Bye BlackBerry and Walmart Gone Wild highlight Gregg Greenberg's list this week.